Business Wire

BOEHRINGER-INGELHEIM

Share
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the forefront of the stromal biology space - an emerging area in cancer immunology. The seller will retain the Northern Biologics name and will continue to drive certain preclinical efforts on one of the programs, while Boehringer Ingelheim will be responsible for clinical, regulatory and commercial development of the acquired programs.

The total transaction includes an upfront payment, milestones and other consideration payments.

The first program, now in late preclinical development, is an antibody inhibitor of Periostin, a secreted matricellular protein overexpressed in the immunosuppressive stroma microenvironment of many solid tumor types. Targeting these stromal cells can help turn previously ‘cold’ tumors – non-reactive, immunologically inactive tumors – to ‘hot’ tumors – those that are susceptible or accessible to host immune system attack. The antibody program targeting Periostin has emerged as a promising therapy to overcome stromal mechanisms of immune exclusion and suppression.

The second program targets a key regulator of myeloid cells that is important for enhancing anti-tumor T-cell function. Targeting myeloid cells is a focus area of research and clinical development for Boehringer Ingelheim and the acquired program offers combination opportunities across Boehringer Ingelheim’s portfolio.

“This acquisition provides Boehringer Ingelheim with two complementary assets to our existing cancer immunology portfolio and supports our strategy to target ‘cold’ tumors with synergistic combination approaches,” said Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head, Cancer Immunology & Immune Modulation Research, Boehringer Ingelheim. “Driving innovation in tumor stroma and myeloid cell biology is yet another example of how we are ‘Taking Cancer On’ by exploring first-in-class approaches to provide the best treatment options for cancer patients.”

“We are gratified by this transaction with Boehringer Ingelheim, which simultaneously accelerates these promising assets into the clinic,” said Philip Vickers, Ph.D., President and CEO of Northern Biologics. “I am proud of the Northern R&D team, which discovered and advanced these compounds in the emerging field of tumor stroma and myeloid cell biology.”

Founding investor Versant Ventures established Northern Biologics in Toronto’s MaRS Discovery District in collaboration with the University of Toronto and Princess Margaret Cancer Centre in 2014. The programs acquired by Boehringer Ingelheim were discovered and translated into clinical candidates by Northern’s Toronto-based research team. Northern Biologics retains rights to its lead asset, MSC-1, an anti-LIF 1 antibody that recently successfully completed Phase 1 clinical trials.

The Northern Biologics-Boehringer Ingelheim acquisition represents the second recent transaction for a Versant-built company operating out of the MaRS discovery district in Toronto. It follows the August 2019 acquisition of BlueRock Therapeutics, which also drew on technology locally developed by Canadian scientists.

This acquisition positions Boehringer Ingelheim as a leader in the field of stromal targeting biology and, along with a series of strategic acquisitions and collaborations over the past two years, further strengthens the company’s broad and diverse oncology pipeline. By combining its world-class, in-house research and development with that of highly innovative biotechnology companies, Boehringer Ingelheim is developing innovative cancer immunology therapies and accelerating the delivery of the next generation of cancer treatments.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/acquisitionofnorthernbiologics

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Clarity AI Acquires ecolytiq, Further Expanding Its AI Sustainability Solutions to End Consumers9.7.2025 13:00:00 CEST | Press release

The acquisition expands on Clarity AI’s market leading climate engagement offering for global retail and commercial banking financial institutions Clarity AI, one of the world’s largest and most awarded technology and AI firms in sustainability, today announced the acquisition of ecolytiq, a leading provider of in-app climate engagement solutions for financial institutions and their millions of retail and commercial banking customers globally. This strategic move further reinforces Clarity AI’s position at the forefront of the rapidly expanding sustainability tech sector, strengthening its dominance in delivering impactful, data-driven solutions that empower individuals and organizations to make more sustainable choices. With this acquisition, Clarity AI expands its class-leading product portfolio, serving a broad spectrum of market participants—from institutional investors and global corporations to retail banks and individual consumers. The company’s modular, AI-powered platform is d

Valorem Reply Brings AI-powered Image Recognition to Art Basel’s Global Fairs9.7.2025 12:57:00 CEST | Press release

Valorem Reply, part of the Reply Group and focused on delivering innovative digital solutions with Microsoft technologies, partnered with Art Basel – a premier international art fair that hosts shows in Basel, Hong Kong, Miami Beach, Paris and Qatar – to enhance the visitor experience. In partnership with Microsoft, they developed Art Basel Lens, a feature within the Art Basel Companion app that uses image recognition to provide real-time information about artworks directly to visitors’ smartphones, making it easier to explore and engage with the art on display. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709262853/en/ With Valorem Reply, Art Basel introduced a mobile image recognition feature that connects audiences to artworks using Microsoft Azure. By scanning an artwork, visitors receive structured content about the piece, the artist, and the gallery. The feature supports a more autonomous and fluid exploration of

Venture Global andSEFEAnnounceExpansion of LNG Partnership9.7.2025 12:19:00 CEST | Press release

Today, Venture Global, Inc. (NYSE: VG) and Securing Energy for Europe GmbH (SEFE) announced the finalization of an agreement under which SEFE’s subsidiary, SEFE Energy GmbH, will purchase an additional 0.75 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from CP2 LNG, Venture Global’s third project, for 20 years. Today’s announcement amends the existing Sales and Purchase Agreement signed by the companies in 2023, increasing the total volume of LNG purchased by SEFE from CP2 LNG to 3.0 MTPA. Venture Global is expected to become Germany’s largest LNG supplier, with a combined 5 MTPA of 20-year offtake agreements signed with SEFE and EnBW. In addition to its existing long-term agreements, Venture Global to date has supplied Germany with almost 80 cargoes of LNG from its Calcasieu Pass and Plaquemines LNG facilities, enough to power 8 million German homes for one year. “Venture Global is thrilled to expand our strategic partnership with Germany and SEFE and play a leading r

The MasterFrame 600, Cooler Master's Modular Full Tower for High-End Builds, Now Available in Europe9.7.2025 10:02:00 CEST | Press release

Inspired by the FreeForm 2.0 philosophy, this revolutionary open-frame chassis is now available across Europe at an MSRP of €199 Cooler Master, a global leader in PC hardware and innovative thermal solutions, today announced the European sales kick-off of the MasterFrame 600, a high-end, modular open-frame full tower designed for power users, creators, and PC modders seeking total creative freedom and high-performance potential. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709203901/en/ Cooler Master's MasterFrame 600 is built on our FreeForm 2.0 philosophy offering owners more customization options for personal builds. The MasterFrame 600 is available across Europe at a suggested retail price of €199, exclusively through select partners and resellers. Engineered on Cooler Master’s FreeForm 2.0 platform, the MasterFrame 600 redefines what’s possible in a premium PC chassis. This open-frame full tower delivers exceptiona

Kaneka Obtains Halal Certificate for KANEKA UBIQUINOL TM9.7.2025 03:30:00 CEST | Press release

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has obtained “Halal Certificate (Certification Number: 355-TSRI/24)” for its functional food ingredient, KANEKA UBIQUINOLTM (active form of coenzyme Q10) powder, under the assessment of Shariah Research Institute of Takushoku University, and issued by JAPAN MUSLIM ASSOCIATION, a religious corporation, on May 28. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708279133/en/ Halal certificate Halal certification is a system in which relevant organizations verify that products or services do not contain ingredients prohibited under Shariah (Islamic law) and certify their compliance with Shariah. We actively pursue the acquisition of various certifications to ensure the safety and security of our raw materials, and we are pleased to announce that we have obtained a Halal Certificate for KANEKA UBIQUINOLTM. Currently, the Muslim populati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye